Synthesis and antioxidant activity of some new coumarinyl-1,3-thiazolidine- 4-ones

Article abstract of DOI:10.3390/molecules15106795

A series of Schiff's bases (E)-N-2-aryliden-2-(4-methyl-2-oxo-2H-chromen-7- yloxy)acetohydrazides 2a-l and N-(2-(substituted phenyl)-4-oxo-thiazolidin-3- yl)-2-(4-methyl-2-oxo-2H-chromen-7-yloxy)acetamides 3a-l were synthesized and evaluated for their ant

Full text of DOI:10.3390/molecules15106795

Molecules 2010, 15, 6795-6809; doi:10.3390/molecules15106795
OPEN ACCESS
molecules
ISSN 1420-3049
www.mdpi.com/journal/molecules
Article
Synthesis and Antioxidant Activity of Some New Coumarinyl-
1,3-Thiazolidine-4-ones
Milan Čačić 1,*, Maja Molnar 1, Bojan Šarkanj 1, Elizabeta Has-Schön 2 and Valentina Rajković 2
1
Department of Applied Chemistry and Ecology, Faculty of Food Technology, J. J. Strossmayer
University, Franje Kuhača 20, 31 000 Osijek, Croatia
2
Department of Biology, J. J. Strossmayer University, Trg Ljudevita Gaja 6, 31 000 osijek, Croatia
* Author to whom correspondence should be addressed; E-Mail: mcacic@ptfos.hr.
Received: 12 June 2010; in revised form: 21 September 2010 / Accepted: 27 September 2010 /
Published: 29 September 2010
Abstract: A series of Schiff’s bases (E)-N-2-aryliden-2-(4-methyl-2-oxo-2H-chromen-7-
yloxy)acetohydrazides 2a-l and N-(2-(substituted phenyl)-4-oxo-thiazolidin-3-yl)-2-(4-
methyl-2-oxo-2H-chromen-7-yloxy)acetamides 3a-l were synthesized and evaluated for
their antioxidant activity by the phosphomolybdenum method. Most of the Schiff’s bases
and thiazolidine-4-ones bearing two hydroxyl groups on the phenyl ring showed excellent
antioxidant activity in comparison with ascorbic acid. Preliminary investigation on
cytotoxic and antifungal activity was done on some representative samples.
Keywords: coumarin; hydrazides; aromatic Schiff’s bases; N-(2-aryl-4-oxo-thiazolidin-3-
yl)-2-(4-methyl-2-oxo-2H-chromen-7-yloxy)acetamide; antioxidant activity; biological
activity
1. Introduction
The structural and therapeutic diversity of small heterocyclic molecules coupled with their
commercial viability has long fascinated organic and medicinal chemists. Heterocycles containing the
coumarin ring system include some novel pharmacologically active compounds such as dicumarol,
warfarin, mercumatilin and novobiocin. Natural coumarins affect the formation and scavenging of
ROS and influence free radical-mediated oxidative damage [1].

Molecules 2010, 15
6796
Azomethine group (-C=N-)-containing compounds, typically known as Schiff’s bases, have been
synthesized via condensation of primary amines with active carbonyls. It is well established that the
biological activity of hydrazone compounds is associated with the presence of the active (-CO-NH-
N=C-) pharmacophore and these compounds form a significant category of compounds in medicinal
and pharmaceutical chemistry with several biological applications that include antitumoral [2,3],
antifungal [4-9], antibacterial [4-11], antimicrobial [12] and anthelmintic uses [13]. Schiff’s base
complexes play an important role in designing metal complexes related to synthetic and natural oxygen
carriers [14].
In recent years, 4-thiazolidinones and 2,4-thiazolidinediones have been among the most extensively
investigated classes of organic compounds. Thiazolidine derivatives are reported to show a variety of
biological activities. The presence of a thiazolidine ring in penicillin and related derivatives was the
first recognition of its occurrence in nature [15]. Thiazolidine-4-one represents a prevalent scaffold in
drug discovery [16]. Literature surveys show that thiazolinylhydrazones exhibit antitubercular and
antimicrobial activities [15], and their pronounced antioxidant [17] and antifungal [18] activity has
also been reported. Thiazolidine-4-ones have many interesting activity profiles, namely COX-1
inhibitors [19], inhibitors of the bacterial enzyme MurB, which was a precursor acting during the
biosynthesis of peptidoglycan [20], non-nucleoside inhibitors of HIV-RT [21] and anti-histaminic
agents [22]. Depending on the substituents, 4-oxothiazolidine ring can induce different
pharmacological properties such as antibacterial [23], antimycobacterial [24], anticonvulsant [25] or
anti-inflammatory activity [26] and it has been reported that the introduction of arylidene moieties at
different positions of the thiazolidinone ring enhanced biological activity [27-29]. Some authors
examined the ability of this ligand structure to form complexes with some radionuclides for potential
use in nuclear medicine [30]. Thus, coumarins containing a Schiff’s base and a thiazolidinone moiety
are expected to have enhanced biological activities.
2. Results and Discussion
2.1. Synthesis
In our ongoing research to synthesize potentially biologically active thiazolidinone derivatives we
have now described a series of (E)-N-2-aryliden-2-(4-methyl-2-oxo-2H-chromen-7-yloxy)aceto-
hydrazides 2a-l and N-(2-aryl-4-oxo-thiazolidine-3-yl)-2-(4-methyl-2-oxo-2H-chromen-7-yloxy)-
acetamides 3a-l (Scheme 1). The series of Schiff’s bases 2a-l was prepared similarly to those
previously described [5,6,12,13,31], by refluxing solutions of different suitable aromatic aldehydes and
hydrazide 1 in absolute ethanol for 2 to 4 hours, in a presence of catalytic amount of glacial acetic acid.
The structures of the products 2a-l were inferred from their analytical and spectral data.
Starting material 1 was prepared as indicated in Scheme 2. Its IR spectrum showed absorption
bands in the 3,317 cm-1 (hydrazide NH-NH2), 3,269 cm-1 (aromatic C-H), 1,711 cm-1(-C=O carbonyl
stretching) and 1,621–1,640 cm-1 (-CO-NH-NH2 groups) regions, respectively. The 1H-NMR spectrum
exhibited a singlet due to the –CO-NH-NH2, NH proton at δ 9.32 ppm. Methylene protons (-OCH2-)
resonated as singlets at 4.85 ppm.

Molecules 2010, 15
Scheme 1. Synthesis of 2,3-disubstituted-1,3-thiazolidine-4-ones 3a-l.
6797
H
N
H2N
O
O
O
O
1
O
Ar
H
H
N
Ar
N
O
O
O
O
2a-l
HSCH2COOH
Ar
S
H
N
O
O
O
N
O
3a-l
O
Entry
Ar
Entry
Ar
a
b
c
d
e
f
2-hydroxyphenyl
2-chlorophenyl
3-chlorophenyl
g
h
i
2,5-dihydroxyphenyl
4-hydroxy-3-methoxyphenyl
3-phenoxyphenyl
2,3-dihydroxyphenyl
2,4-dihydroxyphenyl
3,4-dihydroxyphenyl
j
4-N,N-dimethylaminophenyl
2-hydroxy-5-nitrophenyl
styryl
k
l

Molecules 2010, 15
Scheme 2. Synthesis of (4-methyl-2-oxo-2H-chromen-7-yloxy)acetic acid hydrazide 1.
6798
O
+
Br
O
O
O
OH
acetone, K2CO3
O
O
O
O
O
reflux, 2-4 hours
H2NNH2
ethanol
H
N
O
NH2
O
O
O
1
The IR spectra of compounds 2a-l showed characteristic bands at 3,448–3,278 cm-1 (OH; NH),
1
1,709 cm-1 and 1,672 cm-1(C=O, lactone) and 1,620 cm-1 (C=O, amide, HC=N azomethine). The H-
NMR spectra did not only show the absence of NH2 protons at 3.38, but also the presence of N=CH
proton at 8.30 ppm.
N-(2-aryl-4-oxo-thiazolidine-3-yl)-2-(4-methyl-2-oxo-2H-chromen-7-yloxy) acetamides 3a-l were
obtained by the reaction described in [29], which was performed by refluxing the solutions of Schiff’s
bases 2a-l and thioglycolic acid in 1,4-dioxane in the presence of anhydrous ZnCl2 for 6-8 hours.
Formation of 2,3-disubstituted 4-thiazolidinones 3a-l was confirmed by IR spectroscopy, which
showed the ring C=O stretching characteristic of 1,3-thiazolidine-4-ones ring in the range of νmax
1,690–1,730 cm-1.
1H-NMR spectra for 3a-l showed methylene CH2 (COCH2S) protons of the 4-thiazolidinone ring
between δ 3.34–3.38 ppm as the singlet signal and δ5.26–5.29 ppm for CH (SCHN); proton of the 4-
thiazolidinone ring as a singlet signal.
2.2. Antioxidant activity
Data in Figure 1. show that substituents on the phenyl ring have a great influence on antioxidant
activity. In descending order the effects of the various substituents on the phenyl ring of the Schiff’s

Molecules 2010, 15
6799
bases were found to be: 2,5(OH)2 (2g) > 2,3-(OH)2 (2d) > 3-Cl (2c) > 2,4-(OH)2 (2e) > 3 - phenoxy (2i)
> 3-OCH3-4-OH (2h) > 2-Cl (2b) > styryl (2l) > 4-N(CH3)2 (2j) > 2-OH-5-NO2 (2k)> 2-OH (2a) >
3,4-(OH)2 (2f). Among the Schiff’s compounds 2g and 2d have better antioxidant activities than
ascorbic acid (1.54 and 1.34 times better, respectively). Both of these compounds have two electron
donating OH groups on phenyl ring, one of them being in ortho position in both cases. They also
posses another electron donating group, the presence of which obviously contributes to increased
antioxidant activity, as the compound 2a with only one OH group in the ortho position did not show
relevant antioxidant activity.
Figure 1. Antioxidant activities of novel coumarin derivatives relative to ascorbic acid (Am
– activity relative to ascorbic acid (AA) on a molar basis).
1,8
1,6
1,4
1,2
1
0,8
0,6
0,4
0,2
0
AA 2a 2b 2c 2d 2e 2f 2g 2h 2i 2j 2k 2l 3a 3b 3c 3d 3e 3f 3g 3h 3i 3j 3k 3l
compound
The effects of various substituents on phenyl ring of 1,3-thiazolidine-4-ones in descending order
were found to be: 2,5-(OH)2 (3g) > 2,3-(OH)2 (3d) > 2,4-(OH)2 (3e) > 2-OH (3a) > 3-Cl (3c) > 3,4-
(OH)2 (3f) > 2-OH-5-NO2 (3k) > 3-phenoxy (3i) > 2-Cl (3b) > 4-N(CH3)2 (3j) > 3-OCH3-4-OH (3h) >
styryl (3l). Among the series of 1,3-thiazolidine-4-ones, compounds 3g, 3d and 3e have better
antioxidant activity than ascorbic acid (1.48, 1.41 and 1.40 times better, respectively). All of these
compounds also have two electron donating OH groups on the phenyl ring, one of them being in an
ortho position. Presence of another OH group, no matter the position on the phenyl ring, obviously
contributes to increased antioxidant activity, like in the series of Schiff’s bases.
Observing the overall data for antioxidant activity, it is clear that the presence of two hydroxyl
groups has a great influence on radical scavenging activity. Schiff’s base 2g shows the greatest
antioxidant activity of all investigated compounds, followed by the 1,3-thiazolidine-4-one 3g, both
having 2,5-(OH)2 substituents on phenyl ring, which is in accordance with the results of Lin et al. [32]

Molecules 2010, 15
6800
who reported correlation of radical-scavenging effects of coumarins with the number of hydroxyl
groups.
3. Experimental
3.1. General
The melting points were taken on an Electrothermal capillary melting point apparatus and are
uncorrected. Thin-layer chromatographies were performed using HF254 fluorescent silica gel plates
(Merck), which were examined under UV 254 and 365 nm light. Silica gel (230–400 mesh) was used
for flash chromatography separations. The elemental analysis for C, H and N were done on a Perkin-
Elmer Analyzer 2440. Infrared spectra (ν/cm-1) were recorded on a Beckmann FT-IR 3303 instrument,
using KBr disks. 1H- and 13C-NMR spectra were recorded on JEOL EX-270 MHz NMR Spectrometer
at 293 K in DMSO-d6. Spectra were internally referenced to TMS. Peaks are reported in ppm
downfield of TMS. The absorbance was measured on a Helios γ UV visible spectrophotometer
(Thermo Spectronic, Cambridge, UK).
́
3.2. General procedure for preparation of (E)-N’-arylidene-2-(4-methyl-2-oxo-2H-chromen-7-yloxy)-
acetohydrazides 2a-l
A mixture of compound 1 (0.01 mole) and a suitable aromatic aldehyde (Ar/a-k; 0.01 mole) was
refluxed in absolute ethanol (30 mL) in presence of a catalytic amount of glacial acetic acid for 2 to 4
hours. The reaction mixture was cooled and the precipitate was filtered and recrystallized from
methanol to give compounds 2a-l.
́
(E)-N’-(2-Hydroxybenzylidene)-2-(4-methyl-2-oxo-2H-chromen-7-yloxy)acetohydrazide (2a) [5]. M.p.
284–286 °C; yield (72%); FT-IR: νmax 3,440; 3,282; 3,101; 2,916; 2,853; 1,724; 1,685; 1,621; 1,537;
1,489; 1,393; 1,300 and 1,154 cm-1. 1H-NMR (δ, ppm): 2.41(s, 3H, CH3, C-4); 4.85 (s, 2H, CH2); 6.25
(s, 1H, C-3); 6.87 (s, 1H, H-8), 6.98 (d, 1H, H-6); 7.85 (d, 1H, H-5); 7.25-7.75 (m, 4H, arom.,) 8.33 (s,
1H, NH); 8.56 (s, 1H, HC=N-); 10.99 (s,1H, OH). 13C-NMR (δ, ppm): 21.4 (CH3); 69.10 (OCH2);
107.65 (C-8); 111.0 (C-6); 112.8 (C-3); 113.5 (C-9); 116.1 (C-3, Ar-); 118.4 (C-3, Ar-); 121.7 (C-5,
Ar-); 127.8 (C-5); 130.5 (C-6, Ar-); 132.4 (C-1, Ar-); 161.2 (C-2, Ar-); 143.2 (C=N); 151.4 (C-9);
152.9 (C-4); 160.3 (C-7); 160.9 (C-4); 172.42 (CO-NH). Anal. Calcd. for C19H16N2O5 (352.34): C,
64.77; H, 4.58; N, 8.95. Found: C, 64.76; H, 4.55; N, 7.92
(E)-N´-(2-Chlorobenzylidene)-2-(4-methyl-2-oxo-2H-chromen-7-yloxy)acetohydrazide (2b) [13]. M.p.
248–250 °C; yield (82%). FT-IR: νmax 3,289; 2,950; 2,864; 1,712; 1,700; 1,624; 1,560; 1,525; 1,398;
1,290 and 1,150 cm-1. 1H-NMR (δ, ppm): 2.40 (s, 3H, CH3, C-4); 4.84 (s, 2H, CH2); 6.22 (s, 1H, H-3);
6.99 (s, 1H, H-8); 7.05 (d, 1H, H-6); 7.39-7.75 (m, 4H, arom.); 8.06 (d, 1H, H-5); 8.41(s, 1H, NH);
8.74 (s, 1H, HC=N-). 13C-NMR (δ, ppm): 21.4 (CH3); 69.10 (OCH2); 107.65 (C-8); 111.0 (C-6); 112.8
(C-3); 113.5 (C-9); 127.1 (C-5, Ar-); 127.8 (C-5); 129.1 (C-3, Ar-); 130.4 (C-6, Ar-); 132.5 (C-4, Ar-);
133.2 (C-1, Ar-); 134.2 (C-2, Ar-); 143.2 (C=N); 151.4 (C-9); 152.9 (C-4); 160.3 (C-7); 160.9 (C-2);

Molecules 2010, 15
6801
172.42 (CO-NH). Anal. Calcd. for C19H15ClN2O4 (370.79): C, 61.55; H, 4.08; N, 7.56. Found: C,
61.57; H, 4.08; N, 7.53.
(E)-N´-(3-Chlorobenzylidene)-2-(4-methyl-2-oxo-2H-chromen-7-yloxy)acetohydrazide (2c) [5]. M.p.
242–244 °C; yield (80%). FT-IR: νmax 3,448; 3,201; 3,102; 2,997; 1,713; 1,683; 1,617; 1,511; 1,434;
1,391; 1,274 and 1,136 cm-1. 1H-NMR (δ, ppm): 2.40 (s, 3H, CH3, C-4); 4.82 (s, 2H, CH2); 6.23 (s, 1H,
H-3); 6.98 (s, 1H, H-8); 7.02 (d, 1H, H-6); 7.20 (d, 1H, H-5); 7.41-7.74 (m, 4H, arom.); 8.00 (s, 1H,
NH); 8.31 (s, 1H, HC=N-). 13C-NMR (δ, ppm): 21.4 (CH3); 69.10 (OCH2); 107.65 (C-8); 111.0 (C-6);
112.8 (C-3); 113.5 (C-9); 127.3 (C-6, Ar-); 127.8 (C-5); 129.4 (C-2, Ar-); 130.6 (C-5, Ar-); 131.4 (C-4,
Ar-); 134.5 (C-3, Ar-); 135.2 (C-1, Ar-); 143.2 (C=N); 151.4 (C-9); 152.9 (C-4); 160.3 (C-7); 160.9
(C-2); 172.32 (CO-NH). Anal. Calcd. for C19H15ClN2O4 (370.79): C, 61.55; H, 4.08; N, 9.56. Found: C,
61.54; H, 4.07; N, 7.53.
(E)-N´-(2,3-Dihydroxybenzylidene)-2-(4-methyl-2-oxo-2H-chromen-7-yloxy)acetohydrazide (2d). M.p.
270–274 °C; yield (63%). FT-IR: νmax 3,481; 3,436; 3,332; 3,280; 2,915; 1,719; 1,695; 1,620; 1,541;
1,473; 1,392; 1,265 and 1,153 cm-1. 1H-NMR (δ, ppm): 2.40 (s, 3H, CH3, C-4); 4.84 (s, 2H, CH2); 6.24
(s, 1H, H-3); 6.73 (s, 1H, H-8); 6.85 (d, 1H, H-6); 7.19 (d, 1H, H-5); 6.90-7.75 (m, 3H, arom.); 8.32 (s,
1H, NH); 8.52 (s, 1H, HC=N-); 9.27 (s, br., 1H, OH); 11.59 (s, br., 1H, OH). 13C-NMR (δ, ppm): 21.4
(CH3); 69.10 (OCH2 ); 107.6 (C-8); 111.0 (C-6); 112.8 (C-3); 113.5 (C-9); 119.8 (C-4, Ar-); 120.1 (C-
1, Ar-); 122.6 (C-5, Ar-); 123.5 (C-6, Ar-); 127.8 (C-5); 143.2 (C=N); 147.5 (C-3, Ar-); 151.4 (C-9);
151.8 (C-2, Ar-); 152.9 (C-4); 160.3 (C-7); 160.9 (C-2); 172.42 (CO-NH). Anal. Calcd. for
C19H16N2O6 (368.34): C, 61.95; H, 4.38; N, 7.61. Found: C, 61.93; H, 4.36; N, 7.59.
(E)-N´-(2,4-Dihydroxybenzylidene)-2-(4-methyl-2-oxo-2H-chromen-7-yloxy)acetohydrazide (2e). M.p.
261–262 °C; yield (48%). FT-IR: νmax 3,357; 3,273; 3,169; 3,086; 2,924; 1,716; 1,671; 1,613; 1,512;
1,425; 1,391; 1,264 and 1,152 cm-1. 1H-NMR (δ, ppm): 2.40 (s, 3H, CH3, C-4); 4.84 (s, 2H, CH2); 6.24
(s, 1H, H-3); 6.73 (s, 1H, H-8); 6.85 (d, 1H, H-6); 7.20 (d, 1H, H-5); 6.90-7.75 (m, 3H, arom.); 8.32 (s,
1H, NH); 8.52 (s, 1H, HC=N-); 10.12 (s, br., 1H, OH); 11.40 (s, br., 1H, OH). 13C- NMR (δ, ppm):
21.4 (CH3); 69.10 (OCH2 ); 103.5 (C-3, from Ph); 107.6 (C-8); 108.6 (C-5, Ar-); 111.0 (C-6); 111.3
(C-1, Ar-); 112.8 (C-3); 113.5 (C-9); 127.8 (C-5); 132.5 (C-6, Ar-); 143.2 (C=N); 151.4 (C-9); 152.9
(C-4); 160.3 (C-7); 160.9 (C-2); 162.4 (C-4, Ar-); 162.8 (C-2, Ar-); 172.40 (CO-NH). Anal. Calcd. for
C19H16N2O6 (368.34): C, 61.95; H, 4.38; N, 7.61. Found: C, 61.93; H, 4.39; N, 7.59.
(E)-N´-(3,4-Dihydroxybenzylidene)-2-(4-methyl-2-oxo-2H-chromen-7-yloxy)acetohydrazide (2f). M.p.
243–244 °C; yield (38%). FT-IR: νmax 3,393; 3,239; 3,075; 3,071; 2,980; 1,716; 1,694; 1,612; 1,541;
1
1,509; 1,494; 1,393; 1,262 and 1,159 cm-1. H-NMR(δ, ppm): 2.40 (s, 3H, CH3, C-4); 4.84 (s, 2H,
CH2); 6.24 (s, 1H, H-3); 6.73 (s, 1H, H-8); 6.85 (d, 1H, H-6); 7.20 (d, 1H, H-5); 6.90-7.75 (m, 3H,
arom.); 8.32 (s, 1H, NH); 8.52 (s, 1H, HC=N-); 9.35 (s, br., 1H, OH); 10.14 (s, br., 1H, OH). 13C-NMR
(δ, ppm): 21.4 (CH3); 69.10 (OCH2 ); 107.6 (C-8); 111.0 (C-6); 112.8 (C-3); 113.5 (C-9); 116.8 (C-2,
Ar-); 117.6 (C-5, Ar); 123.5 (C-6, Ar-); 127.3 (C-1, Ar-); 127.8 (C-5); 143.2 (C=N); 143.5 (C-3, Ar-);
149.8 (C-4, Ar-); 151.4 (C-9); 152.9 (C-4); 160.3 (C-7); 160.9 (C-2); 172.42 (CO-NH). Anal. Calcd.
for C19H16N2O6 (368.34): C, 61.95; H, 4.38; N, 7.61. Found: C, 61.90; H, 4.35; N, 7.62.

Molecules 2010, 15
6802
(E)-N´-(2,5-Dihydroxybenzylidene)-2-(4-methyl-2-oxo-2H-chromen-7-yloxy)acetohydrazide (2g). M.p.
273–274 °C; yield (41%). IR: νmax 3,418; 3,276; 3,075; 2,915; 1,705; 1,686; 1,658; 1,622; 1,611; 1,584;
1
1,550; 1,512; 1,428; 1,392; 1,288 and 1,149 cm-1. H-NMR (δ, ppm): 2.40 (s, 3H, CH3, C-4); 4.84 (s,
2H, CH2); 6.24 (s, 1H, H-3); 6.73 (s, 1H, H-8); 6.85 (d, 1H, H-6); 7.20 (d, 1H, H-5); 6.90-7.75 (m, 3H,
arom.,); 8.32 (s, 1H, NH); 8.52 (s, 1H, HC=N-); 9.26 (s, br., 1H, OH); 11.93 (s, br., 1H, OH). 13C-
NMR (δ, ppm): 21.4 (CH3); 69.10 (OCH2); 107.6 (C-8); 111.0 (C-6); 112.8 (C-3); 113.5 (C-9); 116.5
(C-6, Ar-); 117.5 (C-3, Ar-); 119.4 (C-4, Ar-); 120.1 (C-1, Ar-); 127.8 (C-5); 143.2 (C=N); 151.4 (C-9);
151.3 (C-5, Ar-); 152.9 (C-4); 153.8 (C-2, Ar-); 160.3 (C-7); 160.8 (C-2); 172.44 (CO-NH). Anal.
Calcd. for C19H16N2O6 (368.34): C, 61.95; H, 4.38; N, 7.61. Found: C, 61.92; H, 4.37; N, 7.62.
(E)-N´-(4-Hydroxy-3-methoxybenzylidene)-2-(4-methyl-2-oxo-2H-chromen-7-yloxy)
acetohydrazide
(2h) [5]. M.p. 253–254 °C; yield (76%). FT-IR: νmax 3,530; 3,481; 3,319; 3,268; 2,914; 1,720; 1,695;
1,618; 1,540; 1,472; 1,390; 1,265 and 1,153 cm-1. 1H-NMR (δ, ppm): 2.40 (s, 3H, CH3, C-4); 3.82 (3H,
s, OCH3); 4.84 (s, 2H, OCH2); 6.24 (s, 1H, H-3); 6.73 (s, 1H, H-8); 6.85 (d, 1H, H-6); 7.20 (d, 1H, H-
5); 6.90-7.75 (m, 3H, arom.); 8.32 (s, 1H, NH); 8.52 (s, 1H, HC=N-); 11.50 (s, br., 1H, OH). 13C-NMR
(δ, ppm): 21.4 (CH3); 56.2 (OCH3); 69.10 (OCH2 ); 107.6 (C-8);); 111.0 (C-6); 112.8 (C-3); 113.5
(C-9); 114.8 (C-2, Ar-); 117.3 (C-5, Ar-); 123.0 (C-6, Ar-); 127.2 (C-1, Ar-); 127.8 (C-5); 143.2 (C=N);
148.1 (C-4, Ar-); 151.4 (C-9); 151.5 (C-3, Ar-); 152.9 (C-4); 160.3 (C-7); 160.7 (C-2); 172.42 (CO-
NH). Anal. Calcd. for C20H18N2O6 (382.37): C, 62.82; H, 4.74; N, 7.33. Found: C, 62.79; H, 4.73; N,
7.31.
(E)-N´-(3-Phenoxybenzylidene)-2-(4-methyl-2-oxo-2H-chromen-7-yloxy)-acetohydrazide (2i). M.p.
178–180 °C; yield (72%). FT-IR: νmax 3,526; 3,476; 3,329; 3,288; 2,916; 1,723; 1,690; 1,623; 1,544;
1,470; 1,392; 1,265 and 1,153 cm-1. 1H-NMR (δ, ppm): 2.40 (s, 3H, CH3, C-4); 4.84 (s, 2H, CH2); 6.24
(s, 1H, H-3); 6.73 (s, 1H, H-8); 6.85 (d, 1H, H-6); 7.20 (d, 1H, H-5); 6.90-7.75 (m, 9H, arom.,); 8.32 (s,
1H, NH); 8.52 (s, 1H, HC=N-). 13C-NMR (δ, ppm): 21.4 (CH3); 56.2 (OCH3); 69.10 (OCH2); 107.6
(C-8); 111.0 (C-6); 112.8 (C-3); 113.5 (C-9); 116.8 (C-2, Ar-Ph); 117.4 (C-2,6, Ar- PhO); 119.7 (C-4,
Ar- Ph); 121.8 (C-4, Ar-PhO); 122.3 (C-6, Ar- Ph); 127.8 (C-5); 128.5 (C-3,5, Ar-PhO); 128.8 (C-5,
Ar- Ph); 133.6 (C-1, Ar- Ph); 143.2 (C=N); 151.4 (C-9); 152.9 (C-4); 157.1 (C-1, Ar- PhO); 157.3 (C-
3, Ar- Ph); 160.3 (C-7); 160.8 (C-2); 172.40 (CO-NH). Anal. Calcd. for C25H20N2O5 (428.44): C,
70.08; H, 4.71; N, 6.54. Found: C, 70.10; H, 4.72; N, 6.55.
(E)-N´-(4-(Dimethylamino)benzylidene)-2-(4-methyl-2-oxo-2H-chromen-7-yloxy) acetohydrazide (2j)
[6]. M.p. 260–262 °C; yield (86%). FT-IR: νmax 3,528; 3,471; 3,329; 3,285; 2,912; 1,721; 1,695; 1,621;
1
1,541; 1,473; 1,392; 1,265 and 1,153 cm-1. H-NMR (δ, ppm): 2.40 (s, 3H, CH3, C-4); 2.86 (s, 6H,
N(CH3)2); 4.84 (s, 2H, CH2); 6.24 (s, 1H, H-3); 6.73 (s, 1H, H-8); 6.85 (d, 1H, H-6); 7.20 (d, 1H, H-5);
6.90-7.75 (m, 4H, arom.); 8.32 (s, 1H, NH); 8.52 (s, 1H, HC=N-) 13C-NMR, (δ, ppm): 21.4 (CH3);
41.4 (N(CH 3 )2); 69.10 (OCH2 ); 107.6 (C-8); 111.0 (C-6); 112.8 (C-3); 113.5 (C-9); 114.5 (C-3,5, Ar-);
123.04 (C-1, Ar-); 127.8 (C-5); 130.2 (C-2,6, Ar-); 143.2 (C=N); 151.4 (C-10); 151.8 (C-4, Ar-); 152.8
(C-4,coum.); 160.3 (C-7); 160.9 (C-2); 172.42 (CO-NH). Anal. Calcd. For C21H21N3O4 (379.41): C,
66.48; H, 5.58; N, 11.08. Found: C, 66.50; H, 5.57; N, 11.10.

Molecules 2010, 15
6803
(E)-N´-(2-Hydroxy-5-nitrobenzylidene)-2-(4-methyl-2-oxo-2H-chromen-7-yloxy)acetohydrazide (2k).
M.p. 288–290 °C; yield (90%). FT-IR: νmax 3,536; 3,481; 3,329; 3,268; 2,910; 1,724; 1,690; 1,622;
1
1,539; 1,474; 1,390; 1,265 and 1,153 cm-1. H NMR (δ, ppm): 2.40 (s, 3H, CH3, C-4); 4.84 (s, 2H,
CH2); 6.24 (s, 1H, H-3); 6.73 (s, 1H, H-8); 6.85 (d, 1H, H-6); 7.20 (d, 1H, H-5); 6.90-7.75 (m, 3H,
arom.); 8.32 (s, 1H, NH); 8.52 (s, 1H, HC=N-); 11.59 (s, br., 1H, OH). 13C-NMR (δ, ppm): 21.4 (CH3);
69.10 (OCH2); 107.6 (C-8); 111.0 (C-6); 112.8 (C-3); 113.5 (C-9); 117.1 (C-3, Ar-); 119.6 (C-1, Ar-);
120.1 (C-1, Ar-); 124.5 (C-4, Ar-); 125.7 (C-6, Ar-); 127.8 (C-5); 141.3 (C-5, Ar-); 143.2 (C=N);
151.4 (C-9); 152.9 (C-4); 160.3 (C-7); 160.8 (C-2); 167.8 (C-2, Ar-); 172.41 (CO-NH). Anal. Calcd.
for C19 H15N3O7 (397.34): C, 57.43 ; H, 3.81; N,10.58. Found: C, 57.40; H, 3.82; N, 10.54.
(E)-2-(4-Methyl-2-oxo-2H-chromen-7-yloxy)-N´-[(E)-3-phenylallylidene]acetohydrazide (2l) [6]. M.p.
249–250 °C; yield (46%). FT-IR: νmax 3,530; 3,481; 3,339; 3,288; 2,916; 1,720; 1,695; 1,621; 1,541;
1,473; 1,392; 1,265 and 1,153 cm-1. 1H-NMR (δ, ppm): 2.40 (s, 3H, CH3, C-4); 4.84 (s, 2H, CH2); 5.72
(d, 1H, styryl); 6.24 (s, 1H, H-3); 6.63 (d, 1H, styryl); 6.73 (s, 1H, H-8); 6.85 (d, 1H, H-6); 7.20 (d, 1H,
H-5); 6.90-7.75 (m, 3H, arom.); 8.32 (s, 1H, NH); 8.52 (s, 1H, HC=N-). 13C-NMR (δ, ppm): 21.4
(CH3); 69.10 (OCH2); 107.6 (C-8); 111.0 (C-6); 112.8 (C-3); 113.5 (C-9); 126.1 (C-1, Ar-ethenyl);
126.6 (C-2,6, Ar-); 127.8 (C-5); 128.5 (C-4, Ar-); 128.9 (C-3,5, Ar-); 137.2 (C=N); 139.2 (C-2, Ar-
ethenyl); 151.4 (C-10); 152.9 (C-4); 160.3 (C-7); 161.0 (C-2); 172.42 (CO-NH). Anal. Calcd. For
C21H18N2O4 (362.38): C, 69.60; H, 5.01; N, 7.73. Found. C, 69.59; H, 4.99; N, 7.70.
3.3. General procedure for preparation of N-(2-(substituted)-4-oxothiazolidin-3-yl)-2-(4-methyl-2-oxo-
2H-chromen-7-yloxy) acetamides 3a-l [33]
To a solution of (E)-2-(4-methyl-2-oxo-2H-chromen-7-yloxy)-N´-[(E)-3-arylidene]acetohydrazide
2a-l (0.01 mol) in dry 1,4-dioxane (15 mL), freshly distilled mercaptoacetic acid (0.01 mol) and
anhydrous ZnCl2 (0.1 g) were added and the mixture was heated under reflux 10 to 12 hours. The
solvent was removed (reduced pressure) and residue washed with 5% sodium bicarbonate solution (3 ×
20 mL) and water (2 × 20 mL), dried, and recrystallized from an appropriate solvent.
N-(2-(2-Hydroxyphenyl)-4-oxothiazolidin-3-yl)-2-(4-methyl-2-oxo-2H-chromen-7-yloxy)
acetamide
(3a). M.p. 284–286 °C; yield (72%). FT-IR: νmax 3,418; 3,182; 3,100; 2,906; 2,853; 1,725; 1,681;
1
1,623; 1,527; 1,489; 1,393; 1,300 and 1,144 cm-1. H-NMR (δ, ppm): 2.40 (s, 3H, CH3, C-4); 3.34 (s,
2H, COCH2S); 4.84 (s, 2H, OCH2); 5.28 (s, 1H, SCHN); 6.24 (s, 1H, C-3); 6.87 (s, 1H, H-8), 6.98 (d,
13
1H, H-6); 7.25–7.75 (m, 4H, arom.); 8.06 (d, 1H, H-5); 8.33(s, 1H, NH); 10.99 (s, br.,.1H, OH). C-
NMR (δ, ppm): 21.4 (CH3); 32.92 (COCH2S); 69.10 (OCH2); 107.65 (C-8); 111.0 (C-6); 112.8 (C-3);
113.6 (C-10); 116.1 (C-3, Ar-); 118.4 (C-3, Ar-); 121.7 (C-5, Ar-); 127.8 (C-5); 130.5 (C-6, Ar-);
132.4 (C-1, Ar-); 161.2 (C-2, Ar-); 143.2 (CO-N); 151.4 (C-9); 152.9 (C-4); 160.3 (C-7); 160.9 (C-4);
172.45 (CO-NH). Anal. Calcd. for C21H18N2O6S (426.44), C, 59.15; H, 4.25; N, 6.57; S, 7.52. Found:
C, 59.10; H, 4.27; N, 6.54; S, 7.49.
N-(2-(2-Chlorophenyl)-4-oxothiazolidin-3-yl)-2-(4-methyl-2-oxo-2H-chromen-7-yloxy) acetamide (3b)
[26]. M.p. 248–250 °C; yield (82%). FT-IR: νmax 3,280; 2,940; 2,854; 1,722; 1,710; 1,621; 1,580;

Molecules 2010, 15
6804
1,515; 1,394; 1,295 and 1,146 cm-1. 1H-NMR (δ, ppm): 2.40 (s, 3H, CH3, C-4); 3.35 (s, 2H, COCH2S);
4.84 (s, 2H, OCH2); 5.29 (s, 1H, SCHN); 6.22 (s, 1H, H-3); 6.99 (s, 1H, H-8); 7.05 (d, 1H, H-6); 7.39–
7.75 (m, 4H, arom.); 8.06 (d, 1H, H-5); 8.41 (s, 1H, NH). 13C-NMR (δ, ppm): 21.4 (CH3); 32.92
(COCH2S); 47.81 (SCHN); 69.10 (OCH2); 107.65 (C-8); 111.0 (C-6); 112.8 (C-3); 113.4 (C-10);
127.1 (C-5, Ar-); 127.8 (C-5); 129.1 (C-3, Ar-); 130.4 (C-6, Ar-); 132.5 (C-4, Ar-); 133.2 (C-1, Ar-);
134.2 (C-2, Ar-); 143.2 (CO-N); 151.2 (C-19); 152.9 (C-4); 160.3 (C-7); 160.9 (C-2); 172.42 (CO-NH).
Anal. Calcd. for C21H17Cl N2O5S (444.89), C, 56.69; H, 3.85; N, 6.30; S, 7.21. Found: C, 56.70; H,
3.83; N, 6.31; S, 7.20.
N-(2-(3-Chlorophenyl)-4-oxothiazolidin-3-yl)-2-(4-methyl-2-oxo-2H-chromen-7-yloxy) acetamide (3c).
M.p. 242–244 °C; yield (86%). FT-IR: νmax 3,438; 3,200; 3,112; 2,987; 1,723; 1,688; 1,627; 1,516;
1,430; 1,390; 1,264 and 1,136 cm-1. 1H-NMR (δ, ppm): 2.40 (s, 3H, CH3, C-4); 3.38 (s, 2H, COCH2S);
4.82 (s, 2H, CH2); 5.28 (s, 1H, SCHN); 6.23 (s, 1H, H-3); 6.98 (s, 1H, H-8); 7.02 (d, 1H, H-6);
7.41–7.74 (m, 4H, arom.); 8.09 (d, 1H, H-5); 8.40 (s, 1H, NH). 13C-NMR (δ, ppm): 21.4 (CH3); 32.92
(COCH2S); 47.81 (SCHN); 69.10 (OCH2); 107.65 (C-8); 111.0 (C-6); 112.8 (C-3); 113.5 (C-10);
127.3 (C-6, Ar-); 127.8 (C-5); 129.4 (C-2, Ar-); 130.6 (C-5, Ar-); 131.4 (C-4, Ar-); 134.5 (C-3, Ar-);
135.2 (C-1, Ar-); 143.3 (CO-N); 151.4 (C-9); 152.9 (C-4); 160.3 (C-7); 160.9 (C-2); 172.42 (CO-NH).
Anal. Calcd. for C21H17Cl N2O5S (444.89), C, 56.69; H, 3.85; N, 6.30; S, 7.21.Found: C, 56.62; H, 3.82;
N, 6.31; S, 7.24.
N-(2-(2,3-Dihydroxyphenyl)-4-oxothiazolidin-3-yl)-2-(4-methyl-2-oxo-2H-chromen-7-yloxy)
acetamide (3d). M.p. 270–271 °C; yield (63%). FT-IR: νmax 3,531; 3,471; 3,309; 3,268; 2,926; 1,725;
1
1,698; 1,626; 1,551; 1,483; 1,388; 1,260 and 1,143 cm-1. H-NMR (δ, ppm): 2.40 (s, 3H, CH3, C-4);
3.34 (s, 2H, COCH2S); 4.84 (s, 2H, CH2); 5.28 (s, 1H, SCHN); 6.24 (s, 1H, H-3); 6.73 (s, 1H, H-8);
6.85 (d, 1H, H-6); 7.20 (d, 1H, H-5); 6.90–7.75 (m, 3H, arom.); 8.32 (s, 1H, NH); 9.27 (s, br., 1H, OH);
11.59 (s, br., 1H, OH). 13C-NMR (δ, ppm): 21.4 (CH3); 32.92 (COCH2S); 47.81 (SCHN); 69.10
(OCH2); 107.6 (C-8); 111.0 (C-6); 112.8 (C-3); 113.5 (C-10); 119.8 (C-4, Ar-); 120.1 (C-1, Ar-); 122.6
(C-5, Ar-); 123.5 (C-6, Ar-); 127.8 (C-5); 143.2 (CO-N); 147.5 (C-3, Ar-); 151.4 (C-9); 151.8 (C-2,
Ar-); 152.9 (C-4); 160.3 (C-7); 160.9 (C-2); 172.43 (CO-NH). Anal. Calcd. for C21H18N2O7S (442.44),
C, 57.01; H, 4.10; N, 6.33; S, 7.25. Found: C, 57.00; H, 4.08; N, 6.30; S, 7.23.
N-(2-(2,4-Dihydroxyphenyl)-4-oxothiazolidin-3-yl)-2-(4-methyl-2-oxo-2H-chromen-7-yloxy)
acetamide (3e). M.p. 261–262 °C; yield (48%). FT-IR: νmax 3,345; 3,282; 3,172; 3,106; 2,912; 1,726;
1
1,691; 1,622; 1,510; 1,430; 1,382; 1,274 and 1,141 cm-1. H NMR (δ, ppm): 2.40 (s, 3H, CH3, C-4);
3.38 (s, 2H, COCH2S); 4.84 (s, 2H, CH2); 5.29 (s, 1H, SCHN); 6.24 (s, 1H, H-3); 6.73 (s, 1H, H-8);
6.85 (d, 1H, H-6); 7.20 (d, 1H, H-5); 6.90–7.70 (m, 3H, arom.); 8.32 (s, 1H, NH); 10.12 (s, br., 1H,
OH); 11.40 (s, br., 1H, OH). 13C-NMR (δ, ppm): 21.4 (CH3); 32.92 (COCH2S); 47.81 (SCHN); 69.30
(OCH2); 102.7 (C-3, Ar-); 107.9 (C-8); 108.6 (C-5, Ar-); 111.5 (C-6); 111.7 (C-1, Ar-); 112.8 (C-3);
113.6 (C-10); 127.0 (C-5); 132.5 (C-6, Ar-); 143.2 (CO-N); 151.4 (C-9); 152.9 (C-4); 160.4 (C-7);
160.9 (C-2); 162.4 (C-4, Ar-); 162.8 (C-2, Ar-); 172.43 (CO-NH). Anal. Calcd. for C21H18N2O7S
(442.44), C, 57.01; H, 4.10; N, 6.33; S, 7.25. Found: C, 57.04; H, 4.97; N, 6.32; S, 7.29.

Molecules 2010, 15
6805
N-(2-(3,4-Dihydroxyphenyl)-4-oxothiazolidin-3-yl)-2-(4-methyl-2-oxo-2H-chromen-7-yloxy)
acetamide (3f). M.p. 243–244 °C; yield (38%). FT-IR: νmax 3,389; 3,209; 3,045; 3,037; 2,974; 1,726;
1
1,698; 1,612; 1,548; 1,521; 1,489; 1,396; 1,262 and 1,150 cm-1. H-NMR (δ, ppm): 2.40 (s, 3H, CH3,
C-4); 3.35 (s, 2H, COCH2S); 4.84 (s, 2H, CH2); 5.28 (s, 1H, SCHN); 6.24 (s, 1H, H-3); 6.73 (s, 1H, H-
8); 6.85 (d, 1H, H-6); 7.20 (d, 1H, H-5); 6.90-7.65 (m, 3H, arom.); 8.32 (s, 1H, NH); 9.35 (s, br., 1H,
OH); 10.14 (s, br., 1H, OH). 13C-NMR (δ, ppm): 21.4 (CH3); 32.92 (COCH2S); 47.81 (SCHN); 69.10
(OCH2); 107.6 (C-8); 111.0 (C-6); 112.8 (C-3); 113.5 (C-10); 116.8 (C-2, Ar-); 117.6 (C-5, Ar-); 123.5
(C-6, Ar-); 127.3 (C-1, Ar-); 127.8 (C-5); 143.2 (C-N); 143.5 (C-3, Ar-); 149.8 (C-4, Ar-); 151.4 (C-9);
152.9 (C-4); 160.3 (C-7); 160.9 (C-2); 172.42 (CO-NH). Anal. Calcd. for C21H18N2O7S (442.44), C,
57.01; H, 4.10; N, 6.33; S, 7.25. Found: C, 56.99; H, 3.89; N, 6.32; S, 7.24.
N-(2-(2,5-Dihydroxyphenyl)-4-oxothiazolidin-3-yl)-2-(4-methyl-2-oxo-2H-chromen-7-yloxy)
acetamide (3g). M.p. 278–279 °C; yield (41%). FT-IR: νmax 3,420; 3,281; 3,065; 2,915; 1,708; 1,716;
1,688; 1,648; 1,627; 1,581; 1,554; 1,521; 1,418; 1,390; 1,278 and 1,149 cm-1. 1H-NMR (δ, ppm): 2.40
(s, 3H, CH3, C-4); 3.38 (s,2H,COCH2S); 4.84 (s, 2H, CH2); 5.28 (s, 1H, SCHN); 6.24 (s, 1H, H-3);
6.73 (s, 1H, H-8); 6.85 (d, 1H, H-6); 7.20 (d, 1H, H-5); 6.90-7.72 (m, 3H, arom.); 8.32 (s, 1H, NH);
9.26 (s, br., 1H, OH); 11.93 (s, br., 1H, OH). 13C-NMR (δ, ppm): 21.4 (CH3); 32.92 (COCH2S); 47.81
(SCHN); 69.10 (OCH2); 107.6 (C-8); 111.0 (C-6); 112.8 (C-3); 113.5 (C-10); 116.5 (C-6, Ar-); 117.5
(C-3, Ar-); 119.4 (C-4, Ar-); 120.1 (C-1, Ar-); 127.8 (C-5); 143.2 (C-N); 151.4 (C-9); 151.3 (C-5, Ar-);
152.9 (C-4); 153.8 (C-2, Ar-); 160.3 (C-7); 160.9 (C-2); 172.43 (CO-NH). Anal. Calcd. for
C21H18N2O7S (442.44), C, 57.01; H, 4.10; N, 6.33; S, 7.25. Found: C, 57.00; H, 4.08; N, 6.31; S, 7.20.
N-(2-(4-hydroxy-3-methoxyphenyl)-4-oxothiazolidin-3-yl)-2-(4-methyl-2-oxo-2H-chromen-7-yloxy)
acetamide (3h) [23]. M.p. 233–234 °C; yield (76%). FT-IR: νmax 3,517; 3,478; 3,329; 3,274; 2,915;
1
1,723; 1,698; 1,629; 1,536; 1,469; 1,393; 1,255 and 1,145 cm-1. H-NMR (δ, ppm): 2.40 (s, 3H, CH3,
C-4); 3.37 (s, 2H, COCH2S); 3.76 (s, 3H, OCH3); 4.84 (s, 2H, CH2); 5.27 (s, 1H, SCHN); 6.24 (s, 1H,
H-3); 6.73 (s, 1H, H-8); 6.85 (d, 1H, H-6); 7.20 (d, 1H, H-5); 6.90-7.71 (m, 3H, arom.); 8.32 (s, 1H,
NH); 11.59 (s, br., 1H, OH). 13C-NMR (δ, ppm): 21.4 (CH3); 32.92 (COCH2S); 47.81 (SCHN); 56.2
(OCH3); 69.10 (OCH2); 107.6 (C-8); 111.0 (C-6); 112.8 (C-3); 113.5 (C-10); 114.8 (C-2, Ar-); 117.3
(C-5, Ar-); 123.0 (C-6, Ar-); 127.2 (C-1, Ar-); 127.8 (C-5); 143.2 (C-N); 148.1 (C-4, Ar-); 151.4 (C-9);
151.5 (C-3, Ar-); 152.9 (C-4); 160.3 (C-7); 160.9 (C-2); 172.40 (CO-NH). Anal. Calcd. for
C22H20N2O7S (456.47), C, 57.89; H, 4.42; N, 6.14; S, 7.02. Found: C, 57.88; H, 4.39; N, 6.13; S, 7.01.
2-(4-Methyl-2-oxo-2H-chromen-7-yloxy)-N-(4-oxo-2-(3-phenoxyphenyl)thiazolidin-3-yl)
acetamide
(3i). M.p. 217–218 °C; yield (72%). FT-IR: νmax 3,500; 3,471; 3,329; 3,279; 2,910; 1,720; 1,697; 1,619;
1
1,531; 1,467; 1,392; 1,264 and 1,151 cm-1. H-NMR (δ, ppm): 2.40 (s, 3H, CH3, C-4); 3.38 (s, 2H,
COCH2S); 4.84 (s, 2H, CH2); 5.29 (s, 1H, SCHN); 6.24 (s, 1H, H-3); 6.73 (s, 1H, H-8); 6.85 (d, 1H, H-
6); 7.20 (d, 1H, H-5); 6.90-7.76 (m, 9H, arom.); 8.32 (s, 1H, NH). 13C-NMR (δ, ppm), 21.4 (CH3);
32.92 (COCH2S); 47.81 (SCHN); 69.10 (OCH2); 107.6 (C-8); 111.0 (C-6); 112.8 (C-3); 113.5 (C-10);
115.7 (C-4, Ar-Ph); 116.8 (C-2, Ar- Ph); 117.4 (C-2,6, Ar- PhO); 121.8 (C-4, Ar- PhO); 122.3 (C-6,
Ar- Ph); 127.8 (C-5); 128.5 (C-3,5, Ar- PhO); 128.8 (C-5, Ar- Ph); 133.6 (C-1, Ar- Ph); 151.4 (C-9);
152.9 (C-4); 157.1 (C-1, Ar- PhO); 157.3 (C-3, Ar- Ph); 160.3 (C-7); 160.9 (C-2); 166.1 (CO-NH);

Molecules 2010, 15
6806
168.2 (CO-N). Anal. Calcd. for C27H22N2O6S (502.54), C, 64.53; H, 4.41; N, 5.57; S, 6.38. Found: C,
64.50; H, 4.39; N, 5.53; S, 6.39.
N-(2-(4-(Dimethylamino)phenyl)-4-oxothiazolidin-3-yl)-2-(4-methyl-2-oxo-2H-chromen-7-yloxy)-
acetamide (3j). M.p. 227–228 °C; yield (76%). FT-IR: νmax 3,526; 3,473; 3,329; 3,269; 2,926; 1,729;
1
1,690; 1,624; 1,539; 1,473; 1,378; 1,260 and 1,150 cm-1. H-NMR (δ, ppm): 2.40 (s, 3H, CH3, C-4);
2.86 (s, 6H, N(CH3)2); 3.36 (s, 2H, COCH2S); 4.84 (s, 2H, CH2); 5.29 (s, 1H, SCHN); 6.24 (s, 1H, H-
3); 6.73 (s, 1H, H-8); 6.85 (d, 1H, H-6); 7.20 (d, 1H, H-5); 6.90-7.7 (m, 4H, arom.); 8.32 (s, 1H, NH).
13C-NMR (δ, ppm): 21.4 (CH3); 32.92 (COCH2S); 41.4(N(CH3)2); 47.81 (SCHN); 69.10 (OCH2);
107.6 (C-8); 111.0 (C-6); 112.8 (C-3); 113.5 (C-10); 114.5 (C-3,5, Ar-); 123.04 (C-1, Ar); 130.2
(C-2,6, Ar); 143.2 (C-N); 151.4 (C-9); 151.8 (C-4, Ar-); 160.2 (C-7); 160.9 (C-2); 172.43 (CO-NH).
Anal. Calcd. for C23H23N3O5S (453.51), C, 60.91; H, 5.11; N, 9.27; S, 7.07. Found: C, 60.92; H, 5.09;
N, 9.25; S, 7.01.
N-(2-(2-Hydroxy-5-nitrophenyl)-4-oxothiazolidin-3-yl)-2-(4-methyl-2-oxo-2H-chromen-7-yloxy)
acetamide (3k). M.p. 288–290 °C; yield (90%). FT-IR: νmax 3,468; 3,459; 3,329; 3,218; 2,910; 1,720;
1
1,692; 1,625; 1,536; 1,469; 1,386; 1,260 and 1,147 cm-1. H-NMR (δ, ppm): 2.40 (s, 3H, CH3, C-4);
3.37 (s, 2H, COCH2S); 4.84 (s, 2H, CH2); 5.28 (s, 1H, SCHN); 6.24 (s, 1H, H-3); 6.73 (s, 1H, H-8);
6.85 (d, 1H, H-6); 7.20 (d, 1H, H-5); 6.90–7.82 (m, 3H, arom.); 8.32 (s, 1H, NH); 11.54 (s, br., 1H,
OH). 13C-NMR (δ, ppm): 21.4 (CH3); 32.92 (COCH2S); 47.81 (SCHN); 69.10 (OCH2); 107.6 (C-8);
111.0 (C-6); 112.8 (C-3); 113.5 (C-10); 117.1 (C-3, from Ph); 120.1 (C-1, from Ph); 124.5 (C-4, from
Ph); 125.7 (C-6, from Ph); 127.8 (C-5); 141.3 (C-5, from Ph); 143.3 (C-N); 151.4 (C-9); 152.9 (C-4);
160.3 (C-7); 160.9 (C-2); 167.8 (C-2, from Ph); 174.0 (CO-NH). Anal. Calcd. for C21H17N3O8S
(471.44), C, 53.50; H, 3.63; N, 8.91; S, 6.80. Found: C, 53.47; H, 3.64; N, 8.90; S, 6.79.
(E)-2-(4-Methyl-2-oxo-2H-chromen-7-yloxy)-N-(4-oxo-2-styrylhiazolidin-3-yl)acetamide (3l). M.p.
249–250 °C; yield (46%). FT-IR: νmax 3,489; 3,416; 3,309; 3,292; 2,906; 1,728; 1,695; 1,621; 1,543;
1,468; 1,389; 1,254 and 1,131 cm-1. 1H-NMR (δ, ppm): 2.40 (s, 3H, CH3, C-4); 3.36 (s, 2H, COCH2S);
4.84 (s, 2H, CH2); 5.26 (s, 1H, SCHN); 6.13 (d, 1H, styryl); 6.24 (s, 1H, H-3); 6.41 (d, 1H, styryl);
6.73 (s, 1H, H-8); 6.85 (d, 1H, H-6); 7.20 (d, 1H, H-5); 6.94–7.70 (m, 5H, arom.); 8.32 (s, 1H, NH).
13C-NMR (δ, ppm) 21.4 (CH3); 32.92 (COCH2S); 47.81 (SCHN); 69.10 (OCH2); 107.6 (C-8); 111.0
(C-6); 112.8 (C-3); 113.5 (C-9); 126.1 (C-1, styryl); 126.6 (C-2,6, Ar-); 127.8 (C-5); 128.5 (C-4, Ar-);
128.9 (C-3,5, Ar-); 137.2 (C-N); 139.2 (C-2, styryl); 151.4 (C-9); 152.9 (C-4); 160.3 (C-7); 160.9
(C-2); 174.4 (CO-NH). Anal. Calcd. for C23H20N2O5S (436.48), C, 63.29; H, 4.62; N, 6.42; S, 7.35.
Found: C, 63.27; H, 4.61; N, 6.39; S, 7.31.
3.4. Evaluation of antioxidant activity
The antioxidant activity of tested coumarin derivatives was evaluated by the phosphomolybdenum
method according to the procedure in [34]. This method is based on the reduction of Mo(VI) to Mo(V)
by the tested compounds followed by formation of a green phosphate/Mo(V) complex at acid pH. An
aliquot of sample solution (100 μL, 2 mM in DMSO) is mixed with the reagent solution

Molecules 2010, 15
6807
(1 mL, 0.6 M sulphuric acid, 28 mM sodium phosphate and 4 mM ammonium molybdate). The
samples are incubated in a water bath at 95 °C for 90 minutes. Samples are cooled to room temperature
and the absorbance was measured at 695 nm. The antioxidant activity was expressed relative to the
antioxidant activity of same concentration of ascorbic acid.
4. Conclusions
In this study a series of Schiff’s bases (E)-N-2-aryliden-2-(4-methyl-2-oxo-2H-chromen-7-
yloxy)acetohydrazides 2a-l and novel N-(2-(substituted phenyl)-4-oxo-thiazolidin-3-yl)-2-(4-methyl-2-
oxo-2H-chromen-7-yloxy)acetamides 3a-l were synthesized and evaluated for their antioxidant activity
by phosphomolybdenum method. The 1,3-thiazolidine-4-one derivatives containing the coumarin
moiety were synthesized by cyclocondensation of the Schiff's bases and mercaptoacetic acid.
Compounds which are indicated as already known are resynthetized and the analytical data obtained
for these compounds were comparable, but slightly different from those of other authors. For all the
novel compounds structures were elucidated by the means of various spectral methods. Two of the
Schiff’s bases (2g, 2d) and three of 1,3-thiazolidine-4-ones (3g, 3d, 3e) proved to have better
antioxidant activity in comparison with ascorbic acid. In conclusion, it is evident that the substituents
on the phenyl ring have a great influence on antioxidant activity.
References and Notes
1. Fylaktakidou, K.C.; Hadjipavlou-Litina, D.J.; Litinas, K.E.; Nikolaides, D.N. Natural and
synthetic coumarin derivatives with anti-inflammatory/antioxidant activities. Curr. Pharm. Des.
2004, 10, 3813-3833.
2. Mladenova, R.; Ignatova, M.; Manolova, N.; Petrova, T.; Rashkov, I. Preparation, characterization
and biological activity of Schiff base compounds derived from 8-hydroxyquinoline-2-
carboxaldehyde and Jeffamines ED. Eur. Polym. J. 2002, 38, 989-999.
3. Walsh, O.M.; Meegan, M.J.; Prendergast, R.M.; Nakib, T.A. Synthesis of 3-acetoxyazetidin-2-
ones and 3-hydroxyazetidin-2-ones with antifugal and antifungal and antibacterial activity. Eur. J.
Med. Chem. 1996, 31, 989-1000.
4. Singh, K.; Barwa, M.S.; Tyagi, P. Synthesis, characterization and biological studies of Co(II),
Ni(II), Cu(II) and Zn(II) complexes with bidentate Schiff bases derived by heterocyclic ketone.
Eur. J. Med. Chem. 2006, 41, 147-153.
5. Ahluwalia, V.K.; Anand, S.; Goyal, M.: Neghipur, G.A. Synthesis of N-benzylidene derivatives
of 7-hydroxy-4-methyl/phenyl coumarin as potenial fungicides and bactericides. Bokin Bobai
1983, 11, 622-626.
6. Sengupta, A.K.; Sen, S.; Srivastava, V. Synthesis of coumarin derivatives as possible antifungal
and antibacterial agents, J. Ind. Chem. Soc. 1989, 66, 710-716.
7. Panneerselvam, P.; Nair, R.R.; Vijayalakshmi, G.; Subramanian, E.H.; Sridhar, S.K. Synthesis of
Schiff bases of 4-(4-aminophenyl)-morpholine as potential antimicrobial agents. Eur. J. Med.
Chem. 2005, 40, 225-229.
8. Sridhar, S.K.; Saravan, M.; Ramesh, A. Synthesis and antibacterial screening of hydrazones,
Schiff and Mannich bases of isatin derivatives. Eur. J. Med. Chem. 2001, 36, 615-623.

Molecules 2010, 15
6808
9. Pandeya, S.N.; Sriram, D.; Nath, G.; De Clercq, E. Synthesis, antibacterial, antifungal and anti-
HIV activities of Schiff and Mannich bases derived from isatin derivatives and N-[4-(4'-
chlorophenyl)thiazol-2-yl]thiosemicarbazide. Eur. J. Pharmacol. Sci. 1999, 9, 25-31.
10. Abu-Hussen, A.A.A. Synthesis and spectroscopic studies on ternary bis-Schiff-base complexes
having oxygen and/or nitrogen donors. J. Coord. Chem. 2006, 59, 157-176.
11. Karthikeyan, M.S.; Prasad, D.J.; Poojary, B.; Subramanya Bhat, K.; Holl, B.S.; Kumari, N.S.
Synthesis and biological activity of Schiff and Mannich bases bearing 2,4-dichloro-5-
fluorophenyl moiety. Bioorg. Med. Chem. 2006, 14, 7482-7489.
12. Sharma, B.M.; Parsania, M.V.; Baxi, A.J. Synthesis of some azetidinones wih coumarinyl moiety
and their antimicrobial activity. Org. Chem. 2008, 4, 304-308.
13. Husain, M.I.; Shukla, M.A.; Agarwal, S.K. Search for potent anthelmintics. Part VII. Hydrazones
derived from 4-substituted 7-coumarinyloxyacetic acid hydrazides. J. Ind. Chem. Soc. 1979, 56,
306-307.
14. Thangadurai, T.D.; Gowri, M.; Natarajan, K. Synthesis and characterization of ruthenium(III)
complexes containing monobasic bidentate Schiff bases and their biological acivities, Synth.
React. Inorg. Met. Org. Chem. 2002, 32, 329-343.
15. Pulici, M.; Quartieri, F. Traceless Solid-Phase Synthesis of 2-Amino-5-alkylidene-thiazol-4-ones.
Tetrahedron Lett. 2005, 46, 2387-2391.
16. Brown, F.C. 4-Thiazolidinones. Chem. Rev. 1961, 41, 464-511.
17. Manojkumar, P.; Ravi, T.K.; Subbuchettiar, G. Synthesis of coumarin heterocyclic derivatives
with antioxidant activity and in vitro cytotoxic activity against tumour cells. Acta Pharm. 2009,
59, 159-170.
18. Verma, A.; Saraf, S.H. 4-Thiazolidinone – A biologically active scaffold. Eur. J. Med. Chem.
2008, 43, 897-905.
19. Look, G.C.; Schuilck, J.R.; Homes, C.P.; Chinn, J.P.; Gordon, E.M.; Gallop, M.A. The
identification of cyclooxygenase-1 inhibitors from 4-thiazolidine combinatorial, Bioorg. Med.
Chem. Lett. 1996, 6, 707-712.
20. Anders, C.J.; Bronson, J.J.; D'Andrea, S.V.; Despande, M.S.; Falk, P.J.; Grant-Young, K.A.;
Harte, W.E.; Ho, H.T.; Misco, P.F.; Robertson, J.G.; Stock, D.; Sun, Y.; Walsh, A.W. 4-
Thiazolidinones: Novel inhibitors of the bacterial enzyme MurB, Bioorg. Med. Chem. Lett. 2000,
10, 715-717.
21. Barreca, M.L.; Chimiri, A.; De Luca, L.; Monforte, A.M.; Monforte, P.; Rao, A.; Zappala, M.;
Balzarini, J.; De Clercq, E.; Pannecouque, C.; Witvrouw, M. Discovery of 2,3-diaryl-1,3-
thiazolidin-4-ones as potent anti-HIV-1 agents, Bioorg. Med. Chem. Lett. 2001, 1793-1796.
22. Diurno, M.V.; Mazzoni, O.; Piscopo, E.; Calignano, P.E.; Giordano, F.; Bolognese, A. Synhesis
and antihistaminic activity of some thiazolidin-4-ones J. Med. Chem. 1992, 35, 2910-2912.
23. Bonde, C.G.; Gaikwad, N.J. Synhesis and preliminary evaluation of some pyrazine containing
thiazolines and thiazolidinones as antimicrobial agents, Biorg. Med. Chem. 2004, 12, 2151-2161.
24. Kucukguzel, S.G.; Oruc, E.G.; Rolas, S.; Sahin, F.; Ozbek, A. Synthesis, characterisation and
biological activity of novel 4-thiazolidinones, 1,3,4-oxadiazoles and some related compounds Eur.
J. Med. Chem. 2002, 37, 197-206.

Molecules 2010, 15
6809
25. Shyam, R; Tiwari, I.C. Synthesis and spectra of 3-benzyl(or p-tolyl)-5-methyl-2-(substituted
benzothiazol-2′-ylimino)-4-thiazolidones. Bull. Chem. Soc. Japan 1977, 50, 514-516.
26. Taranalli, A.D.; Bhat, A.R.; Srinivas, S.; Saravanan, E. Evaluation of analgesic and anti-
inflammatory activities of thiazolidinone derivatives, J. Cell Tiss. Res. 2007, 7, 1057-1059.
27. Vicini, P.; Zani, F.; Cozzini, P.; Doytchinova, I. Hydrazones of 1,2-benzisothiazole hydrazides:
Synthesis, antimicrobial activity and QSAR investigations. Eur. J. Med. Chem. 2002, 37, 353-364.
28. Zani, F.; Vicini, P.; Incerti, M. Synthesis and antimicrobial properties of 2-(benzylidene-amino)-
benzo[d]isothiazol-3-ones. Eur. J. Med. Chem. 2004, 39, 135-140.
29. Vicini, P.; Geronikaki, A.; Anastasia, K.; Incerti, M.; Zani, F. Synthesis and antimicrobial activity
of novel 2-thiazolylimino-5-arylidene-4-thiazolidinones. Bioorg. Med. Chem. 2006, 14,
3859-3864.
30. Butvin, P.; Mitkova, M.; Svetlik, J.; Havranek, E. Complex Formation of Thiazolidine-2,4-
dicarboxylic Acid with Selected Divalent and Trivalent Metal Ions. Chem. Pap. 2002, 56,
174-177.
31. Cacic, M.; Trkovnik, M.; Cacic, F.; Has-Schön, E. Synthesis and antibacterial acivity of some
derivatives of (7-hydroxy-2-oxo-2H-chromen-4-yl) acetic acid hydrazide. Molecules 2006, 11,
134-147.
32. Lin, H.C.; Tsai, S.H.; Chen, C.S.; Chang, Y.C.; Lee, C.M.; Lai, Z.Y.; Lin, C. M. Structure-activity
relationship of coumarin derivatives on xanthine oxidase-inhibiting and free radical-scavenging
activities. Biochem. Pharmacol. 2008, 75, 1416 – 1425.
33. Cacic, M.; Molnar, M.; Balic, T.; Draca, N.; Rajkovic, V. Design and synthesis of some
thiazolidin-4-ones based on (7-hydroxy-2-oxo-2H-chromen-4-yl) acetic acid. Molecules 2009, 14,
2501-2513.
34. Prieto, P.; Pineda, M.; Aguilar, M. Spectrophotometric quantitation of antioxidant capacity
through the formation of a phosphomolybdenum complex: Specific application to the
determination of vitamin E, Anal. Biochem. 1999, 269, 337-341.
Sample Availability: Samples of all compounds are available from the authors.
© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/3.0/).